Amarin Corp. (AMRN) Misses Q4 EPS by 3c, Sales Beat
Amarin Corp. (NASDAQ: AMRN) reported Q4 EPS of ($0.10), $0.03 worse than the analyst estimate of ($0.07). Revenue for the quarter came in at $38.7 million versus the consensus estimate of $35.08 million.
“2016 was another exceptional year of progress for Amarin both commercially and operationally,” commented John F. Thero, president and chief executive officer. “We begin 2017 with a strong team of motivated people, a product in Vascepa that has a positively differentiated efficacy and safety profile, and managed care coverage for Vascepa that was broad at the start of 2016 and expanded further over the past year. We are pleased to observe key opinion leaders increasing their attention to the potential impacts on public health and the practice of medicine if REDUCE-IT achieves the results we seek and we, of course, look forward to learning the results of this landmark study.”
For earnings history and earnings-related data on Amarin Corp. (AMRN) click here.